Utility of Genomic Profiling Use for Targeted Therapy in a Phase I Setting Reveals that ESCAT I/II Actionable Targets are Associated with Improved Outcomes By Ogkologos - May 6, 2025 474 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CoPPO study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Hormone Therapy for Prostate Cancer? A Genetic Test Could Help Decide March 15, 2021 How Your Primary Care Provider Can Help You Throughout Your Cancer... March 5, 2021 NCI’s Rare Cancer Clinics: Engaging Patients and Fostering Collaboration February 28, 2019 How Does Smoking Increase Your Cancer Risk? An Expert Q&A July 27, 2021 Load more HOT NEWS What People in Asian American and Pacific Islander Communities Should Know... Colorectal Cancer Screening: The Silver Lining Dalpiciclib plus Fulvestrant in Pretreated HR-positive, HER2-negative Advanced Breast Cancer Melanoma Combination Studies with a Novel Anti-LAG3 Antibody Relatlimab
